PD03: Prostate Cancer: Epidemiology & Natural History I

Podium Session Moderator(s)

• 

  Christopher Kane, MD

  University of California San Diego
• RO

  Rubén Olivares, MD

  Associate Staff
  Cleveland Clinic
• WP

  William Parker, MD

  Assistant Professor
  The University of Kansas Health System

Presentations:

• 7:00 AM – 7:10 AM

  PD03-01: MRI as first investigation in men with elevated PSA. Population-based cohort study
  

  Podium Presenter: David Edward Robinsson, MD – Highland Hospital
• 7:10 AM – 7:20 AM

  PD03-02: Long-Term Effects of 5&[alpha]-Reductase Inhibitors on Prostate Cancer Mortality - a Large Population-Based Prospective Study
  

  Podium Presenter: Lars Bjornebo, MSC
• 7:20 AM – 7:30 AM

  PD03-03: Association between 5&[alpha]-reductase Inhibitor and Incidence, Tumor Grading and Survival of Prostate Cancer
  

  Podium Presenter: PengYen Wu, MD – Taichung Veterans General Hospital
• 7:30 AM – 7:40 AM

  PD03-04: Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes
  

  Podium Presenter: Natasha Gupta, MD – NYU Langone Health
• 7:40 AM – 7:50 AM

  PD03-05: Prognostic Value of Lymph Node Count versus Lymph Node Density for Men with Pathological Node-Positive Prostate Cancer
  

  Podium Presenter: Aurash NaserTavakolian, MD
• 7:50 AM – 8:00 AM

  PD03-06: Grade Migration of Prostate Cancer at Diagnosis Following the US Preventive Services Task Force Recommendations on Prostate Cancer Screening
  

  Podium Presenter: Leonardo D. Borregales, MD
• 8:00 AM – 8:10 AM

  PD03-07: Association Between Adverse Surgical Pathology and Overall Survival Among Patients with Low-Risk Prostate Cancer
  

  Podium Presenter: Eileen Lee, BS
• 8:10 AM – 8:20 AM

  PD03-08: The Impact of Medicaid Expansion on Insurance Coverage and Metastatic Disease at Diagnosis in Prostate Cancer Patients
  

  Podium Presenter: David Schroeder
• 8:20 AM – 8:30 AM

  PD03-09: The Natural History of a Detectable Serum PSA after Radical Prostatectomy
  

  Podium Presenter: Julie Szymaniak, MD
• 8:30 AM – 8:40 AM

  PD03-10: Effect of Advances in Treatment on Population-level Survival of Patients with Metastatic Prostate Cancer
  

  Podium Presenter: Camilo Arenas Gallo, MD (he/him/his) – Case Western Reserve University
• 8:40 AM – 8:50 AM

  PD03-11: Patient-reported delays in treatment for urologic cancers during the Covid-19 pandemic: A national cross-sectional analysis
  

  Podium Presenter: Jacob Lang, MSC – University of Toledo College of Medicine
• 8:50 AM – 9:00 AM

  PD03-12: Covid-19 disruption to prostate cancer management in a UK tertiary referral centre
  

  Podium Presenter: Nithesh Mayanka Siripala Ranasinha, BA – Oxford University